Literature DB >> 7495745

Characterization of the non-functional Fas ligand of gld mice.

M Hahne1, M C Peitsch, M Irmler, M Schröter, B Lowin, M Rousseau, C Bron, T Renno, L French, J Tschopp.   

Abstract

Mice homozygous for either the gld or lpr mutation develop autoimmune diseases and progressive lymphadenopathy. The lpr mutation is characterized by the absence of functional Fas, whereas gld mice exhibit an inactive FasL due to a point mutation proximal to the extracellular C-terminus. The structural repercussions of this amino acid substitution remain unknown. Here we report that FasL is expressed at similar levels on the surface of activated T lymphocytes from gld and wild-type mice. Using a polyclonal anti-FasL antibody, indistinguishable amounts of a 40 kDa protein are detected in both gld and wild-type splenocytes. The molecular model of FasL, based on the known structure of TNF-alpha, predicts that the Phe --> Leu gld mutation is located at the protomer interface which is close to the FasR interaction site. We conclude that the gld mutation allows normal FasL biosynthesis, surface expression and oligomerization, but induces structural alterations to the Fas binding region leading to the phenotypic changes observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495745     DOI: 10.1093/intimm/7.9.1381

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  15 in total

Review 1.  Molecular and cellular mechanisms of donor cell-induced tolerance.

Authors:  James F George; Leonik Ahumada; Ailing Lu
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Genetics of SLE in mice.

Authors:  Dwight H Kono; Argyrios N Theofilopoulos
Journal:  Springer Semin Immunopathol       Date:  2006-09-14

3.  Polymorphism of murine Fas ligand that affects the biological activity.

Authors:  N Kayagaki; N Yamaguchi; F Nagao; S Matsuo; H Maeda; K Okumura; H Yagita
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 4.  Targeting Fas in osteoresorptive disorders.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Ana Marusic
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

5.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Characterization and Activation of Fas Ligand-Producing Mouse B Cells and Their Killer Exosomes.

Authors:  Steven K Lundy; Sophina H Taitano; Luciën E P M van der Vlugt
Journal:  Methods Mol Biol       Date:  2021

7.  Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells.

Authors:  A L Wagelie-Steffen; K Hartmann; H Vliagoftis; D D Metcalfe
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

8.  Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer.

Authors:  Guang-Zhou Wu; Chun-Xia Pan; Dong Jiang; Qiang Zhang; Yin Li; Shi-Ying Zheng
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

9.  Lymphopenia associated with highly virulent H5N1 virus infection due to plasmacytoid dendritic cell-mediated apoptosis of T cells.

Authors:  Kobporn Boonnak; Leatrice Vogel; Friederike Feldmann; Heinz Feldmann; Kevin L Legge; Kanta Subbarao
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

Review 10.  Apoptosis: molecular regulation of cell death and hematologic malignancies.

Authors:  Vincenzo Chiarugi; Marina Cinelli; Lucia Magnelli; Sbarba Persio Dello
Journal:  Mol Biotechnol       Date:  2002-03       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.